Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorte Glintborg

Showing results (11-20 of 173) with videos related to

Pageof 18
Sort By:
Ugeskrift for Laeger|October 23, 2008
[Risk stratification of patients with diabetes mellitus]Peter Qvist, Dorte Glintborg, Alin Andries, et al.
Ugeskrift for Laeger|March 7, 2009
[The National List of recommendations-- what is it based on?]Jens P Kampmann, Dorte Glintborg, Mikael Juul Bygsø
Metabolites|December 23, 2022
Myoinositol vs. Metformin in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical TrialPernille Ravn, Freja Gram, Marianne S Andersen, et al.
The Journal of Clinical Endocrinology and Metabolism|November 11, 2017
Response to Letter to the Editor: "Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome"Dorte Glintborg, Katrine Hass Rubin, Bo Abrahamsen, et al.
Endocrine Connections|April 23, 2017
Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndromeDorte Glintborg, Hanne Mumm, Jens Juul Holst, et al.
Fertility and Sterility|October 11, 2011
Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndromeLine Velling Magnussen, Hanne Mumm, Marianne Andersen, et al.
Clinical Endocrinology|June 10, 2005
Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutismDorte Glintborg, Marianne Andersen, Claus Hagen, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|April 17, 2018
Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndromeMagda Lambaa Altinok, Pernille Ravn, Marianne Andersen, et al.
European Journal of Endocrinology|June 3, 2021
MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender peopleDorte Glintborg, Guy T'Sjoen, Pernille Ravn, et al.
Clinical Endocrinology|January 28, 2009
Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatmentDorte Glintborg, Marianne Andersen, Bjørn Richelsen, et al.
Pageof 18

Showing results (11-20 of 173) with videos related to

Sort By:
Pageof 18
Ugeskrift for Laeger|October 23, 2008
[Risk stratification of patients with diabetes mellitus]Peter Qvist, Dorte Glintborg, Alin Andries, et al.
Ugeskrift for Laeger|March 7, 2009
[The National List of recommendations-- what is it based on?]Jens P Kampmann, Dorte Glintborg, Mikael Juul Bygsø
Metabolites|December 23, 2022
Myoinositol vs. Metformin in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical TrialPernille Ravn, Freja Gram, Marianne S Andersen, et al.
The Journal of Clinical Endocrinology and Metabolism|November 11, 2017
Response to Letter to the Editor: "Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome"Dorte Glintborg, Katrine Hass Rubin, Bo Abrahamsen, et al.
Endocrine Connections|April 23, 2017
Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndromeDorte Glintborg, Hanne Mumm, Jens Juul Holst, et al.
Fertility and Sterility|October 11, 2011
Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndromeLine Velling Magnussen, Hanne Mumm, Marianne Andersen, et al.
Clinical Endocrinology|June 10, 2005
Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutismDorte Glintborg, Marianne Andersen, Claus Hagen, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|April 17, 2018
Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndromeMagda Lambaa Altinok, Pernille Ravn, Marianne Andersen, et al.
European Journal of Endocrinology|June 3, 2021
MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender peopleDorte Glintborg, Guy T'Sjoen, Pernille Ravn, et al.
Clinical Endocrinology|January 28, 2009
Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatmentDorte Glintborg, Marianne Andersen, Bjørn Richelsen, et al.
Pageof 18